|Description||Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders.|
|B0084-067210||100 mg||$298||In stock|
|Synonyms||BAY59-7939; BAY 59-7939; BAY-59-7939; Rivaroxaban; trade name: Xarelto.|
Eribaxaban is an orally active inhibitor of coagulation factor Xa (activated factor X). It has anticoagulant activity and is used as an anticoagulant drug. It i...
Betrixaban is a long-acting anticoagulant used for the treatment of venous thromboembolism (VTE) caused by limited mobility or some other factors in adult patie...
The sodium salt form of Ozagrel which has been studied to influence monophenolase and diphenolase activities and also restrain the synthesis of thromboxane A2 s...
Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembol...
Edoxaban is an oral factor Xa (FXa) inhibitor, also contraindicated in patients with active pathological bleeding.
BMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa with Ki of 0.03 nM.
BMS-344577 is aroylguanidine-based lactam derivative, which is a potent FXa inhibitor (FXa IC(50)=4 nM, EC(2xPT)=7 microM).
Gabexate is a serine protease inhibitor that inhibits trypsin (IC50= 9.4μM), plasmin (IC50= 30μM), plasma kallikrein (IC50= 41μM) and thrombin (IC50= 110μM). It...